A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Trial of the Effects of Intravenous GC4419 on the Incidence and Duration of Severe Oral Mucositis (OM) in Patients Receiving Post-Operative or Definitive Therapy with Single-Agent Cisplatin plus IMRT for Locally Advanced, Non-Metastatic Squamous Cell Carcinoma of the Oral Cavity or Oropharynx
To determine the effects of investigational medication GC4419 on oral mucositis in patients being treated with chemotherapy and radiation therapy for squamous cell carcinoma of the oral cavity or oropharynx.
Squamous cell carcinoma of the head and neck (SCCHN)
Patients with diagnosis of squamous cell carcinoma of the head and neck who are 18 years of age and older. Patients must not have received prior chemotherapy or radiation therapy but plan to be treated this way.
18 - 100
Healthy Volunteers Needed
Duration of Participation
Sr. Research Assistant
Oregon Health & Science University
Department of Radiation Medicine
Galera Therapeutics, Inc.